Shanghai Fosun Pharma Buys Majority of Hunan Dongting for $93 Million

Published: Jan 07, 2013

by Richard Daverman, PhD and Henry Ye

January 7, 2013 -- Shanghai Fosun Pharma continued to execute on its growth-by-acquisition strategy by paying $93 million for a 78% stake in Hunan Dongting Pharmaceutical Co., a company that makes CNS and hemostatic drugs. Donging’s major product is quetiapine fumarate, marketed in global markets as Seroquel, an AstraZeneca treatment for schizophrenia and bipolar disorder. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (NYSE: AZN)

Back to news